Digital Therapeutics Market by Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS) Disease, Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID), and Others), Product Type (Software and Device), and Sales Channel (Business-to-Business (B2B), Business-to-Consumer (B2C)): Global Opportunity Analysis and Industry Forecast, 2020–2027
The global digital therapeutics market was valued at $2.88 billion in 2019, and is expected to reach $13.80 billion by 2027 with a CAGR of 20.5% during the forecast period.
Digital therapeutics provides evidence-based therapeutic interventions to patients. It is driven by software programs and devices to prevent, manage, or treat a medical condition. Digital therapeutics software application can be used independently or in combination with devices, medications, or any other therapies to provide patient care and health outcomes. These products incorporate advanced technology, best practices regarding design, usability, clinical validation, and data security. These products are reviewed and approved by regulatory bodies before use. Furthermore, digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.
Increase in adoption of smartphones and tablets, coupled with healthcare apps, growth in need to control healthcare cost, and rise in incidences of chronic diseases drive growth of the global digital therapeutics market. However, lack of awareness regarding digital therapeutics in developing countries and patient data privacy concerns restrain the market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 20.5% from 2020 to 2027. On the contrary, emerging markets are anticipated to offer significant growth opportunities for the market players in the future.
The global digital therapeutics market is segmented into application, product type, sales channel, and region. By application, it is divided into diabetes, obesity, cardio vascular diseases (CVD), central nervous system (CNS) disease, respiratory diseases, smoking cessation, gastrointestinal disorders, and others. By product type, it is classified into software and devices. Further, on the basis of sales channel, it is bifurcated into business-to-business (B2B) and business-to-consumers (B2C). Furthermore, business-to-business (B2B) is categorized into employers, healthcare providers, and others. By business-to-consumers, it is classified into patients and caregivers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
Digital therapeutics provides evidence-based therapeutic interventions to patients. It is driven by software programs and devices to prevent, manage, or treat a medical condition. Digital therapeutics software application can be used independently or in combination with devices, medications, or any other therapies to provide patient care and health outcomes. These products incorporate advanced technology, best practices regarding design, usability, clinical validation, and data security. These products are reviewed and approved by regulatory bodies before use. Furthermore, digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.
Increase in adoption of smartphones and tablets, coupled with healthcare apps, growth in need to control healthcare cost, and rise in incidences of chronic diseases drive growth of the global digital therapeutics market. However, lack of awareness regarding digital therapeutics in developing countries and patient data privacy concerns restrain the market growth. The impact of the driving factors is expected to surpass that of the restraints. Hence, the market is projected to grow at a CAGR of 20.5% from 2020 to 2027. On the contrary, emerging markets are anticipated to offer significant growth opportunities for the market players in the future.
The global digital therapeutics market is segmented into application, product type, sales channel, and region. By application, it is divided into diabetes, obesity, cardio vascular diseases (CVD), central nervous system (CNS) disease, respiratory diseases, smoking cessation, gastrointestinal disorders, and others. By product type, it is classified into software and devices. Further, on the basis of sales channel, it is bifurcated into business-to-business (B2B) and business-to-consumers (B2C). Furthermore, business-to-business (B2B) is categorized into employers, healthcare providers, and others. By business-to-consumers, it is classified into patients and caregivers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the global digital therapeutics market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
- By Application
- Diabetes
- Obesity
- Cardiovascular Disease (CVD)
- Central Nervous System (CNS) Disease
- Respiratory Disease
- Smoking Cessation
- Gastrointestinal Disorder (GID)
- Others
- By Product Type
- Software
- Device
- By Sales Channel
- Business-to-Business (B2B)
- Employer
- Healthcare Provider
- Others
- Business-to-Consumer (B2C)
- Patient
- Caregiver
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Australia
- Japan
- India
- China
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA
- 2MORROW, Inc.
- Akili Interactive Labs, Inc.
- Click Therapeutics, Inc.
- Fitbit, Inc. (Twine Health, Inc.)
- Happify, Inc.
- Kaia Health
- Livongo Health, Inc.
- Medtronic Plc.
- Omada Health, Inc.
- Pear Therapeutics, Inc.
- Proteus Digital Health, Inc.
- Resmed, Inc. (Propeller Health)
- Voluntis, Inc.
- Welldoc, Inc.
- Canary Health Inc.
- Mango Health Inc.
- Noom, Inc.
- Dthera Sciences
CHAPTER 1: INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key Market Segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning, 2019
3.4.Porter’s five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in adoption of smartphones and tablets, coupled with healthcare apps
3.5.1.2.Growth in need to control healthcare costs
3.5.1.3.Rise in incidences of chronic diseases
3.5.2.Restraints
3.5.2.1.Lack of awareness regarding digital therapeutics in developing countries
3.5.2.2.Patient data privacy concerns
3.5.3.Opportunity
3.5.3.1.Emerging markets offer significant growth opportunities
3.6.Impact analysis of COVID-19 on the digital therapeutics market
3.7.Impact of government regulations on global digital therapeutics market
3.7.1.U.S. FDA’s premarket clearance and approval requirements
3.7.2.European Union premarket clearance and approval requirements
3.7.3.Japan premarket clearance and approval requirements
3.8.Strategy adopted by top 10 start-ups
3.8.1.Meru Health, Inc.
3.8.2.Bold Health Limited
3.8.3.BehaVR, LLC
3.8.4.Naluri Hidup Sdn Bhd
3.8.5.Big Health
3.8.6.Hinge Health, Inc.
3.8.7.Glooko, Inc.
3.8.8.Holmusk Pte. Ltd.
3.8.9.Wellthy Therapeutics Pvt Ltd.
3.8.10.Virta Health Corp.
3.9.Key digital technologies for digital therapeutics
3.9.1.Mobile health (mHealth)
3.9.2.Personalized healthcare
3.9.3.Digital Cognitive Behavior Therapy (CBT)
3.9.4.Wearable devices and sensors
3.10.Necessary human resources required for digital therapeutics development
3.11.Usage of patient data acquired from digital therapeutics
3.11.1.Types of personal information that are collected by DTx companies
CHAPTER 4: DIGITAL THERAPEUTICS MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Diabetes
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Obesity
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Cardiovascular diseases
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Central nervous system (CNS) diseases
4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.6.Gastrointestinal disorder
4.6.1.Key market trends and growth opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
4.7.Respiratory diseases
4.7.1.Key market trends and growth opportunities
4.7.2.Market size and forecast
4.7.3.Market analysis, by country
4.8.Smoking cessation
4.8.1.Key market trends and growth opportunities
4.8.2.Market size and forecast
4.8.3.Market analysis, by country
4.9.Others
4.9.1.Key market trends and growth opportunities
4.9.2.Market size and forecast
4.9.3.Market analysis, by country
CHAPTER 5: DIGITAL THERAPEUTICS MARKET, BY PRODUCT
5.1.Overview
5.1.1.Market size and forecast
5.2.Software
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Devices
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
CHAPTER 6: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Business-to-business (B2B)
6.2.1.Market size and forecast, by type
6.2.1.1.Employer
6.2.1.1.1.Market size and forecast
6.2.1.2.Healthcare Providers
6.2.1.2.1.Market size and forecast
6.2.1.3.Others
6.2.1.3.1.Market size and forecast
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.Business-to-consumers
6.3.1.Market size and forecast, by type
6.3.1.1.Patients
6.3.1.1.1.Market size and forecast
6.3.1.2.Caregivers
6.3.1.2.1.Market size and forecast
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
CHAPTER 7: DIGITAL THERAPEUTICS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America digital therapeutics market, by country
7.2.2.1.U.S. digital therapeutics market, by application
7.2.2.2.U.S digital therapeutics market, by product type
7.2.2.3.U.S. digital therapeutics market, by sales channel
7.2.2.4.Canada digital therapeutics market, by application
7.2.2.5.Canada digital therapeutics market, by product type
7.2.2.6.Canada digital therapeutics market, by sales channel
7.2.2.7.Mexico digital therapeutics market, by application
7.2.2.8.Mexico digital therapeutics market, by product type
7.2.2.9.Mexico digital therapeutics market, by sales channel
7.2.3.North America digital therapeutics market, by application
7.2.4.North America digital therapeutics market, by product type
7.2.5.North America digital therapeutics market, by sales channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe digital therapeutics market, by country
7.3.2.1.UK digital therapeutics market, by application
7.3.2.2.UK digital therapeutics market, by product type
7.3.2.3.UK digital therapeutics market, by sales channel
7.3.2.4.Germany digital therapeutics market, by application
7.3.2.5.Germany digital therapeutics market, by product type
7.3.2.6.Germany digital therapeutics market, by sales channel
7.3.2.7.France digital therapeutics market, by application
7.3.2.8.France digital therapeutics market, by product type
7.3.2.9.France digital therapeutics market, by sales channel
7.3.2.10.Italy digital therapeutics market, by application
7.3.2.11.Italy digital therapeutics market, by product type
7.3.2.12.Italy digital therapeutics market, by sales channel
7.3.2.13.Spain digital therapeutics market, by application
7.3.2.14.Spain digital therapeutics market, by product type
7.3.2.15.Spain digital therapeutics market, by sales channel
7.3.2.16.Rest of Europe digital therapeutics market, by application
7.3.2.17.Rest of Europe digital therapeutics market, by product type
7.3.2.18.Rest of Europe digital therapeutics market, by sales channel
7.3.3.Europe digital therapeutics market, by application
7.3.4.Europe digital therapeutics market, by product type
7.3.5.Europe digital therapeutics market, by sales channel
7.4.Asia-pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific digital therapeutics market, by country
7.4.2.1.Japan digital therapeutics market, by application
7.4.2.2.Japan digital therapeutics market, by product type
7.4.2.3.Japan digital therapeutics market, by sales channel
7.4.2.4.China digital therapeutics market, by application
7.4.2.5.China digital therapeutics market, by product type
7.4.2.6.China digital therapeutics market, by sales channel
7.4.2.7.Australia digital therapeutics market, by application
7.4.2.8.Australia digital therapeutics market, by product type
7.4.2.9.Australia digital therapeutics market, by sales channel
7.4.2.10.India digital therapeutics market, by application
7.4.2.11.India digital therapeutics market, by product type
7.4.2.12.India digital therapeutics market, by sales channel
7.4.2.13.South Korea digital therapeutics market, by application
7.4.2.14.South Korea digital therapeutics market, by product type
7.4.2.15.South Korea digital therapeutics market, by sales channel
7.4.2.16.Rest of Asia-Pacific digital therapeutics market, by application
7.4.2.17.Rest of Asia-Pacific digital therapeutics market, by product type
7.4.2.18.Rest of Asia-Pacific digital therapeutics market, by sales channel
7.4.3.Asia-Pacific digital therapeutics market, by application
7.4.4.Asia-Pacific digital therapeutics market, by product type
7.4.5.Asia-Pacific digital therapeutics market, by sales channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA digital therapeutics market, by country
7.5.2.1.Brazil digital therapeutics market, by application
7.5.2.2.Brazil digital therapeutics market, by product type
7.5.2.3.Brazil digital therapeutics market, by sales channel
7.5.2.4.Turkey digital therapeutics market, by application
7.5.2.5.Turkey digital therapeutics market, by product type
7.5.2.6.Turkey digital therapeutics market, by sales channel
7.5.2.7.Saudi Arabia digital therapeutics market, by application
7.5.2.8.Saudi Arabia digital therapeutics market, by product type
7.5.2.9.Saudi Arabia digital therapeutics market, by sales channel
7.5.2.10.South Africa digital therapeutics market, by application
7.5.2.11.South Africa digital therapeutics market, by product type
7.5.2.12.South Africa digital therapeutics market, by sales channel
7.5.2.13.Rest of LAMEA digital therapeutics market, by application
7.5.2.14.Rest of LAMEA digital therapeutics market, by product type
7.5.2.15.Rest of LAMEA digital therapeutics market, by sales channel
7.5.3.LAMEA digital therapeutics market, by application
7.5.4.LAMEA digital therapeutics market, by product type
7.5.5.LAMEA digital therapeutics market, by sales channel
CHAPTER 8: COMPANY PROFILES
8.1.2MORROW, INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Key strategic moves and developments
8.2.AKILI INTERACTIVE LABS, INC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio
8.2.4.Key strategic moves and developments
8.3.CLICK THERAPEUTICS, INC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Key strategic moves and developments
8.4.FITBIT, INC. (TWINE HEALTH, INC.)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance
8.4.5.Key strategic moves and developments
8.5.HAPPIFY, INC.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Product portfolio
8.5.4.Key strategic moves and developments
8.6.KAIA HEALTH
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Product portfolio
8.6.4.Key strategic moves and developments
8.7.LIVONGO HEALTH, INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Product portfolio
8.7.4.Key strategic moves and developments
8.8.MEDTRONIC PLC.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.OMADA HEALTH, INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Key strategic moves and developments
8.10.PEAR THERAPEUTICS, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Key strategic moves and developments
8.11.PROTEUS DIGITAL HEALTH, INC.
8.11.1.Company overview
8.11.2.Company snapshot
8.11.3.Operating business segments
8.11.4.Product portfolio
8.11.5.Key strategic moves and developments
8.12.RESMED, INC. (PROPELLER HEALTH)
8.12.1.Company overview
8.12.2.Company snapshot
8.12.3.Operating business segments
8.12.4.Product portfolio
8.12.5.Business performance
8.12.6.Key strategic moves and developments
8.13.VOLUNTIS, INC.
8.13.1.Company overview
8.13.2.Company snapshot
8.13.3.Operating business segments
8.13.4.Product portfolio
8.13.5.Business performance
8.13.6.Key strategic moves and developments
8.14.WELLDOC, INC.
8.14.1.Company overview
8.14.2.Company snapshot
8.14.3.Operating business segments
8.14.4.Product portfolio
8.14.5.Key strategic moves and developments
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key Market Segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning, 2019
3.4.Porter’s five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in adoption of smartphones and tablets, coupled with healthcare apps
3.5.1.2.Growth in need to control healthcare costs
3.5.1.3.Rise in incidences of chronic diseases
3.5.2.Restraints
3.5.2.1.Lack of awareness regarding digital therapeutics in developing countries
3.5.2.2.Patient data privacy concerns
3.5.3.Opportunity
3.5.3.1.Emerging markets offer significant growth opportunities
3.6.Impact analysis of COVID-19 on the digital therapeutics market
3.7.Impact of government regulations on global digital therapeutics market
3.7.1.U.S. FDA’s premarket clearance and approval requirements
3.7.2.European Union premarket clearance and approval requirements
3.7.3.Japan premarket clearance and approval requirements
3.8.Strategy adopted by top 10 start-ups
3.8.1.Meru Health, Inc.
3.8.2.Bold Health Limited
3.8.3.BehaVR, LLC
3.8.4.Naluri Hidup Sdn Bhd
3.8.5.Big Health
3.8.6.Hinge Health, Inc.
3.8.7.Glooko, Inc.
3.8.8.Holmusk Pte. Ltd.
3.8.9.Wellthy Therapeutics Pvt Ltd.
3.8.10.Virta Health Corp.
3.9.Key digital technologies for digital therapeutics
3.9.1.Mobile health (mHealth)
3.9.2.Personalized healthcare
3.9.3.Digital Cognitive Behavior Therapy (CBT)
3.9.4.Wearable devices and sensors
3.10.Necessary human resources required for digital therapeutics development
3.11.Usage of patient data acquired from digital therapeutics
3.11.1.Types of personal information that are collected by DTx companies
CHAPTER 4: DIGITAL THERAPEUTICS MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Diabetes
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Obesity
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Cardiovascular diseases
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Central nervous system (CNS) diseases
4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.6.Gastrointestinal disorder
4.6.1.Key market trends and growth opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
4.7.Respiratory diseases
4.7.1.Key market trends and growth opportunities
4.7.2.Market size and forecast
4.7.3.Market analysis, by country
4.8.Smoking cessation
4.8.1.Key market trends and growth opportunities
4.8.2.Market size and forecast
4.8.3.Market analysis, by country
4.9.Others
4.9.1.Key market trends and growth opportunities
4.9.2.Market size and forecast
4.9.3.Market analysis, by country
CHAPTER 5: DIGITAL THERAPEUTICS MARKET, BY PRODUCT
5.1.Overview
5.1.1.Market size and forecast
5.2.Software
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Devices
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
CHAPTER 6: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Business-to-business (B2B)
6.2.1.Market size and forecast, by type
6.2.1.1.Employer
6.2.1.1.1.Market size and forecast
6.2.1.2.Healthcare Providers
6.2.1.2.1.Market size and forecast
6.2.1.3.Others
6.2.1.3.1.Market size and forecast
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.Business-to-consumers
6.3.1.Market size and forecast, by type
6.3.1.1.Patients
6.3.1.1.1.Market size and forecast
6.3.1.2.Caregivers
6.3.1.2.1.Market size and forecast
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
CHAPTER 7: DIGITAL THERAPEUTICS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America digital therapeutics market, by country
7.2.2.1.U.S. digital therapeutics market, by application
7.2.2.2.U.S digital therapeutics market, by product type
7.2.2.3.U.S. digital therapeutics market, by sales channel
7.2.2.4.Canada digital therapeutics market, by application
7.2.2.5.Canada digital therapeutics market, by product type
7.2.2.6.Canada digital therapeutics market, by sales channel
7.2.2.7.Mexico digital therapeutics market, by application
7.2.2.8.Mexico digital therapeutics market, by product type
7.2.2.9.Mexico digital therapeutics market, by sales channel
7.2.3.North America digital therapeutics market, by application
7.2.4.North America digital therapeutics market, by product type
7.2.5.North America digital therapeutics market, by sales channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe digital therapeutics market, by country
7.3.2.1.UK digital therapeutics market, by application
7.3.2.2.UK digital therapeutics market, by product type
7.3.2.3.UK digital therapeutics market, by sales channel
7.3.2.4.Germany digital therapeutics market, by application
7.3.2.5.Germany digital therapeutics market, by product type
7.3.2.6.Germany digital therapeutics market, by sales channel
7.3.2.7.France digital therapeutics market, by application
7.3.2.8.France digital therapeutics market, by product type
7.3.2.9.France digital therapeutics market, by sales channel
7.3.2.10.Italy digital therapeutics market, by application
7.3.2.11.Italy digital therapeutics market, by product type
7.3.2.12.Italy digital therapeutics market, by sales channel
7.3.2.13.Spain digital therapeutics market, by application
7.3.2.14.Spain digital therapeutics market, by product type
7.3.2.15.Spain digital therapeutics market, by sales channel
7.3.2.16.Rest of Europe digital therapeutics market, by application
7.3.2.17.Rest of Europe digital therapeutics market, by product type
7.3.2.18.Rest of Europe digital therapeutics market, by sales channel
7.3.3.Europe digital therapeutics market, by application
7.3.4.Europe digital therapeutics market, by product type
7.3.5.Europe digital therapeutics market, by sales channel
7.4.Asia-pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific digital therapeutics market, by country
7.4.2.1.Japan digital therapeutics market, by application
7.4.2.2.Japan digital therapeutics market, by product type
7.4.2.3.Japan digital therapeutics market, by sales channel
7.4.2.4.China digital therapeutics market, by application
7.4.2.5.China digital therapeutics market, by product type
7.4.2.6.China digital therapeutics market, by sales channel
7.4.2.7.Australia digital therapeutics market, by application
7.4.2.8.Australia digital therapeutics market, by product type
7.4.2.9.Australia digital therapeutics market, by sales channel
7.4.2.10.India digital therapeutics market, by application
7.4.2.11.India digital therapeutics market, by product type
7.4.2.12.India digital therapeutics market, by sales channel
7.4.2.13.South Korea digital therapeutics market, by application
7.4.2.14.South Korea digital therapeutics market, by product type
7.4.2.15.South Korea digital therapeutics market, by sales channel
7.4.2.16.Rest of Asia-Pacific digital therapeutics market, by application
7.4.2.17.Rest of Asia-Pacific digital therapeutics market, by product type
7.4.2.18.Rest of Asia-Pacific digital therapeutics market, by sales channel
7.4.3.Asia-Pacific digital therapeutics market, by application
7.4.4.Asia-Pacific digital therapeutics market, by product type
7.4.5.Asia-Pacific digital therapeutics market, by sales channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA digital therapeutics market, by country
7.5.2.1.Brazil digital therapeutics market, by application
7.5.2.2.Brazil digital therapeutics market, by product type
7.5.2.3.Brazil digital therapeutics market, by sales channel
7.5.2.4.Turkey digital therapeutics market, by application
7.5.2.5.Turkey digital therapeutics market, by product type
7.5.2.6.Turkey digital therapeutics market, by sales channel
7.5.2.7.Saudi Arabia digital therapeutics market, by application
7.5.2.8.Saudi Arabia digital therapeutics market, by product type
7.5.2.9.Saudi Arabia digital therapeutics market, by sales channel
7.5.2.10.South Africa digital therapeutics market, by application
7.5.2.11.South Africa digital therapeutics market, by product type
7.5.2.12.South Africa digital therapeutics market, by sales channel
7.5.2.13.Rest of LAMEA digital therapeutics market, by application
7.5.2.14.Rest of LAMEA digital therapeutics market, by product type
7.5.2.15.Rest of LAMEA digital therapeutics market, by sales channel
7.5.3.LAMEA digital therapeutics market, by application
7.5.4.LAMEA digital therapeutics market, by product type
7.5.5.LAMEA digital therapeutics market, by sales channel
CHAPTER 8: COMPANY PROFILES
8.1.2MORROW, INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Key strategic moves and developments
8.2.AKILI INTERACTIVE LABS, INC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Product portfolio
8.2.4.Key strategic moves and developments
8.3.CLICK THERAPEUTICS, INC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Key strategic moves and developments
8.4.FITBIT, INC. (TWINE HEALTH, INC.)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance
8.4.5.Key strategic moves and developments
8.5.HAPPIFY, INC.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Product portfolio
8.5.4.Key strategic moves and developments
8.6.KAIA HEALTH
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Product portfolio
8.6.4.Key strategic moves and developments
8.7.LIVONGO HEALTH, INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Product portfolio
8.7.4.Key strategic moves and developments
8.8.MEDTRONIC PLC.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.OMADA HEALTH, INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Key strategic moves and developments
8.10.PEAR THERAPEUTICS, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Key strategic moves and developments
8.11.PROTEUS DIGITAL HEALTH, INC.
8.11.1.Company overview
8.11.2.Company snapshot
8.11.3.Operating business segments
8.11.4.Product portfolio
8.11.5.Key strategic moves and developments
8.12.RESMED, INC. (PROPELLER HEALTH)
8.12.1.Company overview
8.12.2.Company snapshot
8.12.3.Operating business segments
8.12.4.Product portfolio
8.12.5.Business performance
8.12.6.Key strategic moves and developments
8.13.VOLUNTIS, INC.
8.13.1.Company overview
8.13.2.Company snapshot
8.13.3.Operating business segments
8.13.4.Product portfolio
8.13.5.Business performance
8.13.6.Key strategic moves and developments
8.14.WELLDOC, INC.
8.14.1.Company overview
8.14.2.Company snapshot
8.14.3.Operating business segments
8.14.4.Product portfolio
8.14.5.Key strategic moves and developments
LIST OF TABLES
TABLE 01.FDA CLASSIFICATION OF MEDICAL DEVICES
TABLE 02.DIGITAL SKILLS REQUIRED FOR EMPLOYEES DEDICATED FOR DTX DEVELOPMENTS
TABLE 03.RANGE OF NUMBER OF EMPLOYEES WITH DIGITAL SKILLS DEDICATED FOR DIGITAL THERAPEUTICS DEVELOPMENTS, BY COMPANY
TABLE 04.GLOBAL DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 05.DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2019–2027 ($MILLION)
TABLE 06.DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2019–2027 ($MILLION)
TABLE 07.DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2027 ($MILLION)
TABLE 08.DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM DISEASES, BY REGION, 2019–2027 ($MILLION)
TABLE 09.SMART PILLS FOR CAPSULE ENDOSCOPY, DRUG DELIVERY, AND PATIENT MONITORING AVAILABLE IN THE MARKET
TABLE 10.DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDER, BY REGION, 2019–2027 ($MILLION)
TABLE 11.DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2019–2027 ($MILLION)
TABLE 12.DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2019–2027 ($MILLION)
TABLE 13.DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 14.GLOBAL DIGITAL THERAPEUTICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 15.DIGITAL THERAPEUTIC APPLICATIONS AND SOFTWARE PLATFORMS
TABLE 16.GLOBAL DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY REGION, 2019–2027 ($MILLION)
TABLE 17.GLOBAL DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY REGION, 2019–2027 ($MILLION)
TABLE 18.GLOBAL DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 19.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY TYPE, 2019–2027 ($MILLION)
TABLE 20.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY REGION, 2019–2027 ($MILLION)
TABLE 21.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY TYPE, 2019–2027 ($MILLION)
TABLE 22.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY REGION, 2019–2027 ($MILLION)
TABLE 23.DIGITAL THERAPEUTICS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 24.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 25.U.S. DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 26.U.S. DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 27.U.S. DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 28.CANADA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 29.CANADA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 30.CANADA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 31.MEXICO DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 32.MEXICO DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 33.MEXICO DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 34.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 35.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 36.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 37.EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 38.UK DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 39.UK DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 40.UK DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 41.GERMANY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 42.GERMANY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 43.GERMANY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 44.FRANCE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 45.FRANCE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 46.FRANCE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 47.ITALY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 48.ITALY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 49.ITALY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 50.SPAIN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 51.SPAIN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 52.SPAIN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 53.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 54.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 55.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 56.EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 57.EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 58.EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 59.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.JAPAN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 61.JAPAN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 62.JAPAN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 63.CHINA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 64.CHINA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 65.CHINA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 66.AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 67.AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 68.AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 69.INDIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 70.INDIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 71.INDIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 72.SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 73.SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 74.SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 76.REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 77.REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 78.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 79.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 80.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 81.LAMEA DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 82.BRAZIL DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 83.BRAZIL DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 84.BRAZIL DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 85.TURKEY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 86.TURKEY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 87.TURKEY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 88.SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 89.SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 90.SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 91.SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 92.SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 93.SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 94.REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 95.REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 96.REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 97.LAMEA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 98.LAMEA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 99.LAMEA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 100.2MORROW: COMPANY SNAPSHOT
TABLE 101.WELLDOC: PRODUCT PORTFOLIO
TABLE 102.AKILI: COMPANY SNAPSHOT
TABLE 103.AKILI: PRODUCT PORTFOLIO
TABLE 104.CLICK THERAPEUTICS: COMPANY SNAPSHOT
TABLE 105.CLICK THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 106.FITBIT: COMPANY SNAPSHOT
TABLE 107.FITBIT: PRODUCT PORTFOLIO
TABLE 108.HAPPIFY: COMPANY SNAPSHOT
TABLE 109.HAPPIFY: PRODUCT PORTFOLIO
TABLE 110.KAIA: COMPANY SNAPSHOT
TABLE 111.KAIA: PRODUCT PORTFOLIO
TABLE 112.LIVONGO: COMPANY SNAPSHOT
TABLE 113.LIVONGO: PRODUCT PORTFOLIO
TABLE 114.MEDTRONIC: COMPANY SNAPSHOT
TABLE 115.MEDTRONIC: OPERATING SEGMENTS
TABLE 116.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 117.OMADA: COMPANY SNAPSHOT
TABLE 118.OMADA: PRODUCT PORTFOLIO
TABLE 119.PEAR: COMPANY SNAPSHOT
TABLE 120.PEAR: PRODUCT PORTFOLIO
TABLE 121.PROTEUS: COMPANY SNAPSHOT
TABLE 122.PROTEUS: PRODUCT PORTFOLIO
TABLE 123.RESMED: COMPANY SNAPSHOT
TABLE 124.RESMED: OPERATING SEGMENTS
TABLE 125.RESMED: PRODUCT PORTFOLIO
TABLE 126.VOLUNTIS: COMPANY SNAPSHOT
TABLE 127.VOLUNTIS: OPERATING SEGMENTS
TABLE 128.VOLUNTIS: PRODUCT PORTFOLIO
TABLE 129.WELLDOC: COMPANY SNAPSHOT
TABLE 130.WELLDOC: PRODUCT PORTFOLIO
TABLE 01.FDA CLASSIFICATION OF MEDICAL DEVICES
TABLE 02.DIGITAL SKILLS REQUIRED FOR EMPLOYEES DEDICATED FOR DTX DEVELOPMENTS
TABLE 03.RANGE OF NUMBER OF EMPLOYEES WITH DIGITAL SKILLS DEDICATED FOR DIGITAL THERAPEUTICS DEVELOPMENTS, BY COMPANY
TABLE 04.GLOBAL DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 05.DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2019–2027 ($MILLION)
TABLE 06.DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2019–2027 ($MILLION)
TABLE 07.DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2027 ($MILLION)
TABLE 08.DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM DISEASES, BY REGION, 2019–2027 ($MILLION)
TABLE 09.SMART PILLS FOR CAPSULE ENDOSCOPY, DRUG DELIVERY, AND PATIENT MONITORING AVAILABLE IN THE MARKET
TABLE 10.DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDER, BY REGION, 2019–2027 ($MILLION)
TABLE 11.DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2019–2027 ($MILLION)
TABLE 12.DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2019–2027 ($MILLION)
TABLE 13.DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 14.GLOBAL DIGITAL THERAPEUTICS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 15.DIGITAL THERAPEUTIC APPLICATIONS AND SOFTWARE PLATFORMS
TABLE 16.GLOBAL DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY REGION, 2019–2027 ($MILLION)
TABLE 17.GLOBAL DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY REGION, 2019–2027 ($MILLION)
TABLE 18.GLOBAL DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 19.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY TYPE, 2019–2027 ($MILLION)
TABLE 20.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY REGION, 2019–2027 ($MILLION)
TABLE 21.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY TYPE, 2019–2027 ($MILLION)
TABLE 22.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY REGION, 2019–2027 ($MILLION)
TABLE 23.DIGITAL THERAPEUTICS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 24.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 25.U.S. DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 26.U.S. DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 27.U.S. DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 28.CANADA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 29.CANADA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 30.CANADA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 31.MEXICO DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 32.MEXICO DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 33.MEXICO DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 34.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 35.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 36.NORTH AMERICA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 37.EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 38.UK DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 39.UK DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 40.UK DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 41.GERMANY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 42.GERMANY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 43.GERMANY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 44.FRANCE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 45.FRANCE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 46.FRANCE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 47.ITALY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 48.ITALY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 49.ITALY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 50.SPAIN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 51.SPAIN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 52.SPAIN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 53.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 54.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 55.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 56.EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 57.EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 58.EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 59.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.JAPAN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 61.JAPAN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 62.JAPAN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 63.CHINA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 64.CHINA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 65.CHINA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 66.AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 67.AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 68.AUSTRALIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 69.INDIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 70.INDIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 71.INDIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 72.SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 73.SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 74.SOUTH KOREA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 76.REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 77.REST OF ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 78.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 79.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 80.ASIA-PACIFIC DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 81.LAMEA DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 82.BRAZIL DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 83.BRAZIL DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 84.BRAZIL DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 85.TURKEY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 86.TURKEY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 87.TURKEY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 88.SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 89.SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 90.SAUDI ARABIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 91.SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 92.SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 93.SOUTH AFRICA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 94.REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 95.REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 96.REST OF LAMEA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 97.LAMEA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 98.LAMEA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 99.LAMEA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 100.2MORROW: COMPANY SNAPSHOT
TABLE 101.WELLDOC: PRODUCT PORTFOLIO
TABLE 102.AKILI: COMPANY SNAPSHOT
TABLE 103.AKILI: PRODUCT PORTFOLIO
TABLE 104.CLICK THERAPEUTICS: COMPANY SNAPSHOT
TABLE 105.CLICK THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 106.FITBIT: COMPANY SNAPSHOT
TABLE 107.FITBIT: PRODUCT PORTFOLIO
TABLE 108.HAPPIFY: COMPANY SNAPSHOT
TABLE 109.HAPPIFY: PRODUCT PORTFOLIO
TABLE 110.KAIA: COMPANY SNAPSHOT
TABLE 111.KAIA: PRODUCT PORTFOLIO
TABLE 112.LIVONGO: COMPANY SNAPSHOT
TABLE 113.LIVONGO: PRODUCT PORTFOLIO
TABLE 114.MEDTRONIC: COMPANY SNAPSHOT
TABLE 115.MEDTRONIC: OPERATING SEGMENTS
TABLE 116.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 117.OMADA: COMPANY SNAPSHOT
TABLE 118.OMADA: PRODUCT PORTFOLIO
TABLE 119.PEAR: COMPANY SNAPSHOT
TABLE 120.PEAR: PRODUCT PORTFOLIO
TABLE 121.PROTEUS: COMPANY SNAPSHOT
TABLE 122.PROTEUS: PRODUCT PORTFOLIO
TABLE 123.RESMED: COMPANY SNAPSHOT
TABLE 124.RESMED: OPERATING SEGMENTS
TABLE 125.RESMED: PRODUCT PORTFOLIO
TABLE 126.VOLUNTIS: COMPANY SNAPSHOT
TABLE 127.VOLUNTIS: OPERATING SEGMENTS
TABLE 128.VOLUNTIS: PRODUCT PORTFOLIO
TABLE 129.WELLDOC: COMPANY SNAPSHOT
TABLE 130.WELLDOC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.DIGITAL THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKET IN DIGITAL THERAPEUTICS MARKET, 2019
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2016–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2016–2020*
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH BARGAINING POWER OF BUYERS
FIGURE 09.LOW THREAT OF SUBSTITUTION
FIGURE 10.MODERATE THREAT OF NEW ENTRANT
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.GLOBAL DIGITAL THERAPEUTICS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 13.DIGITAL THERAPEUTICS MARKET, BY APPLICATION
FIGURE 14.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY COUNTRY, 2019 & 2027, ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM DISEASES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDER, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 22.DIGITAL THERAPEUTICS MARKET, BY PRODUCT
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY COUNTRY, 2017 & 2024 (%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 25.DIGITAL THERAPEUTICS MARKET BY SALES CHANNEL
FIGURE 26.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY EMPLOYER, 2019–2027 ($MILLION)
FIGURE 27.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY HEALTHCARE PROVIDERS, 2019–2027 ($MILLION)
FIGURE 28.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY OTHERS, 2019–2027 ($MILLION)
FIGURE 29.COMPARATIVE ANALYSIS OF BUSINESS-TO-BUSINESS MARKET, BY COUNTRY 2019 & 2027 ($MILLION)
FIGURE 30.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY PATIENTS, 2019–2027 ($MILLION)
FIGURE 31.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY CAREGIVERS, 2019–2027 ($MILLION)
FIGURE 32.COMPARATIVE ANALYSIS OF BUSINESS-TO-CONSUMERS, BY COUNTRY 2019 & 2027 ($MILLION)
FIGURE 33.FITBIT: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.FITBIT: NET SALES, BY REGION, 2019 (%)
FIGURE 35.MEDTRONIC: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.MEDTRONIC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.RESMED: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.RESMED: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.VOLUNTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.VOLUNTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 42.VOLUNTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 01.DIGITAL THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKET IN DIGITAL THERAPEUTICS MARKET, 2019
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2016–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2016–2020*
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH BARGAINING POWER OF BUYERS
FIGURE 09.LOW THREAT OF SUBSTITUTION
FIGURE 10.MODERATE THREAT OF NEW ENTRANT
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.GLOBAL DIGITAL THERAPEUTICS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 13.DIGITAL THERAPEUTICS MARKET, BY APPLICATION
FIGURE 14.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY COUNTRY, 2019 & 2027, ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM DISEASES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDER, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 22.DIGITAL THERAPEUTICS MARKET, BY PRODUCT
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY COUNTRY, 2017 & 2024 (%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 25.DIGITAL THERAPEUTICS MARKET BY SALES CHANNEL
FIGURE 26.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY EMPLOYER, 2019–2027 ($MILLION)
FIGURE 27.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY HEALTHCARE PROVIDERS, 2019–2027 ($MILLION)
FIGURE 28.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY OTHERS, 2019–2027 ($MILLION)
FIGURE 29.COMPARATIVE ANALYSIS OF BUSINESS-TO-BUSINESS MARKET, BY COUNTRY 2019 & 2027 ($MILLION)
FIGURE 30.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY PATIENTS, 2019–2027 ($MILLION)
FIGURE 31.DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY CAREGIVERS, 2019–2027 ($MILLION)
FIGURE 32.COMPARATIVE ANALYSIS OF BUSINESS-TO-CONSUMERS, BY COUNTRY 2019 & 2027 ($MILLION)
FIGURE 33.FITBIT: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.FITBIT: NET SALES, BY REGION, 2019 (%)
FIGURE 35.MEDTRONIC: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.MEDTRONIC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.RESMED: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.RESMED: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.VOLUNTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.VOLUNTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 42.VOLUNTIS: REVENUE SHARE, BY REGION, 2019 (%)
